» Articles » PMID: 31431921

Precision Medicine and Its Role in the Treatment of Sepsis: A Personalised View

Overview
Publisher Sciendo
Specialty Critical Care
Date 2019 Aug 22
PMID 31431921
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, a new form of medicine has become increasingly significant, namely, personalised medicine (PM). PM is a form of care in which treatment is tailored for an individual patient. PM is about using multiple data sets to create a digital human mapping. A person's biological traits are determined by the interactions of hundreds of genes and gene networks, as well as external factors such as diet and exercise. Combining and then investigating these multiple databases with powerful statistical tools, allows a new understanding of how genetic intricacy drives health and disease and so leads to a closer personalised medical approach that targets each individual's unique genetic make-up. Sepsis is a systemic inflammatory response to infection, ranging from systemic inflammatory response syndrome (SIRS) to septic shock and multiple organ dysfunction syndromes (MODS). Sepsis is the most common cause of death in intensive care patients. Treatments in an ICU may need to be adapted to the continuous and rapid changes of the disease, making it challenging to identify a single target. PM is thus seen as the future of sepsis treatment in the ICU. The fact that individual patients respond differently to treatment should be regarded as a starting point in the approach to providing treatment. The disease itself comes secondary to this concept.

Citing Articles

Is Carboxyhaemoglobin an Effective Bedside Prognostic Tool for Sepsis and Septic Shock Patients?.

Grigorescu B, Coman O, Vasiesiu A, Bacarea A, Petrisor M, Saplacan I J Crit Care Med (Targu Mures). 2023; 9(4):239-251.

PMID: 37969884 PMC: 10644283. DOI: 10.2478/jccm-2023-0031.


The Human Microbiome in Intensive Care - A Journey Forward?.

Azamfirei L J Crit Care Med (Targu Mures). 2023; 9(4):205-207.

PMID: 37969883 PMC: 10644287. DOI: 10.2478/jccm-2023-0032.


Fluid Therapy from Friend to Foe.

Fodor R J Crit Care Med (Targu Mures). 2023; 9(3):135-137.

PMID: 37588185 PMC: 10425928. DOI: 10.2478/jccm-2023-0019.


Unifying cardiovascular modelling with deep reinforcement learning for uncertainty aware control of sepsis treatment.

Nanayakkara T, Clermont G, Langmead C, Swigon D PLOS Digit Health. 2023; 1(2):e0000012.

PMID: 36812511 PMC: 9931225. DOI: 10.1371/journal.pdig.0000012.


Pharmacogenetics in critical care: association between CYP3A5 rs776746 A/G genotype and acetaminophen response in sepsis and septic shock.

Scorcella C, Domizi R, Amoroso S, Carsetti A, Casarotta E, Castaldo P BMC Anesthesiol. 2023; 23(1):55.

PMID: 36797680 PMC: 9933278. DOI: 10.1186/s12871-023-02018-y.


References
1.
Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman S, Martin C . Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med. 2004; 171(5):461-8. DOI: 10.1164/rccm.200403-324OC. View

2.
Wong H, Wheeler D, Tegtmeyer K, Poynter S, Kaplan J, Chima R . Toward a clinically feasible gene expression-based subclassification strategy for septic shock: proof of concept. Crit Care Med. 2010; 38(10):1955-61. PMC: 2943553. DOI: 10.1097/CCM.0b013e3181eb924f. View

3.
Garnett M, Edelman E, Heidorn S, Greenman C, Dastur A, Lau K . Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-5. PMC: 3349233. DOI: 10.1038/nature11005. View

4.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

5.
King E, Bauza G, Mella J, Remick D . Pathophysiologic mechanisms in septic shock. Lab Invest. 2013; 94(1):4-12. PMC: 5656285. DOI: 10.1038/labinvest.2013.110. View